Replies to post #207944 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

IV administered as well....not friendly.

[PlentyParanoid]

I personally would not put much stock on medians when severe OM duration reduction is concerned. OM duration distributions seem to be truly weird things - I would love to see Kaplan-Meier curves and LogRank p values for them, not this median plus quartiles crap that's being published (voice from pharma research bunker: dream on, bozo).

For example: Palifermin a.k.a. Kepivance claims SOM median duration reduction of 70 % over placebo but reduction at 3rd quartile is only about 20%. Meaning: there is HELLUVA FAT TAIL in Kepivance's OM duration distribution and the area under duration curve is not nearly that much reduced as comparison based on median claims - Kaplan Meier with LogRank would expose that.

Insurance companies, being sensible businesses, calculate treatment costs and hence their reason to reimburse based on means not medians. Most of the time, unfortunately, clinical trials don't even try to estimate mean. But, naturally, drug co's are averse of volunteering any useful info - Nitwits.

I guess my level of pissed offedness is showing. Sorry.